Primary CD30-Positive T-Cell Lymphoproliferative Disorder

Primary CD30-Positive T-Cell Lymphoproliferative Disorder — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03409432	Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma	completed	Phase 2	26	John ReneauOTHER	1	Aug 13, 2026	clinicaltrials
NCT07717580	Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)(BV-LISA-CTCL)	not yet recruiting	Phase 2	46	Peking University First HospitalOTHER	1	Jul 23, 2026	clinicaltrials
NCT01352520	SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)	active not recruiting	Phase 2	79	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT03587844

Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials